Effect of Rosuvastatin on Fasting and Postprandial Lipid Profile in Hypertriglyceridemia Patients

Authors : Abdulkadir ÇAKMAK

Pages : 146-155

Doi:10.22399/ijcesen.827419

View : 19 | Download : 13

Publication Date : 2021-11-30

Article Type : Research Paper

Abstract :Abstract: Background: Coronary heart disease insert ignore into journalissuearticles values(CHD); is a main cause of mortality due to cardiovascular diseases. Hypertriglyceridemia insert ignore into journalissuearticles values(HTG); is a multifactorial condition implicated in the pathogenesis of CHD. Serum triglyceride insert ignore into journalissuearticles values(TG); levels were routinely obtained under fasting conditions; however, recent evidences implicate that postprandial triglyceride levels may be more important for CHD risk. Aim: Aim of this study was to investigate the effect of rosuvastatin on fasting and postprandial TG levels in the patients with borderline-high TG levels. Methods: 51 patients insert ignore into journalissuearticles values(18-75 years old; 26 female); with LDL-c between 100 and 160 mg/dL and triglyceride levels between 150 and 300 mg/dL were included in this study. Basal fasting and postprandial lipid profile and hsCRP levels of the patients were obtained and patients were requested to take 10 mg/day rosuvastatin for one month. At the end of one month, the measurements were repeated. Results: Rosuvastatin significantly decreased both fasting and postprandial TG levels compared to basal levels insert ignore into journalissuearticles values(p<0.001);. The decrease in the postprandial TG levels after rosuvastatin treatment were significantly higher than the decrease in fasting TG levels insert ignore into journalissuearticles values(p<0.001);. No differences between genders were observed with regards to decrease in the fasting and postprandial TG levels. In patients with metabolic syndrome, rosuvastatin treatment decreased fasting and postprandial TG levels after one month, however, the change was not different from the patients without metabolic syndrome. Conclusion: In conclusion, the decrease in postprandial TG levels after rosuvastatin treatment that was shown may be clinically important in prevention of CHD in HTG patients.
Keywords : Coronary heart disease, Hypertriglyceridemia, Rosuvastatin, Triglycerides